The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the first new approval for the condition since tocilizumab in ...

Left untreated, temporal arteritis can lead to blindness and increases the risk of aneurysms, strokes, and other vascular problems. This makes it one of the few headache conditions considered a ...

SELECT-GCA (M16-852) is a phase 3, multicenter, randomized, double-blind placebo-controlled study designed ... sustained remission in the first period. Giant cell arteritis (GCA), also known as ...

RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common ...

GCA is an autoimmune disease that causes inflammation of the temporal and other cranial arteries ... and potentially severe outcomes, such as blindness, aortic aneurysm, or stroke.

Learn about eye changes that could indicate serious health conditions, from blurry vision to persistent floaters and flashes ...